Windtree Therapeutics (WINT) has released an update to notify the public and investors about an entry into a material definitive agreement.
Windtree Therapeutics, Inc. and Deerfield Management Company affiliates renegotiated their 2017 milestone-based agreement regarding the AEROSURF® development program. Under the new terms, Deerfield waived its rights to future milestone payments, initially worth up to $15 million, in exchange for $200,000 in cash—half paid immediately, half to be paid by January 2025 or upon the company’s successful fundraising—and 608,272 shares of Windtree’s common stock. Additionally, a Registration Rights Agreement was signed to facilitate the resale of these shares, with details outlined in regulatory filings.
For further insights into WINT stock, check out TipRanks’ Stock Analysis page.
